Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: An overview

Neurology

Volumn 49, Issue 1 SUPPL., 1997, Pages

  Stern, Matthew B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; SELEGILINE;

ARTICLE; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DRUG RESEARCH; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; NEUROPROTECTION; PARKINSON DISEASE; PATIENT CARE; PRIORITY JOURNAL;

EID: 0030871412     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.49.1_suppl_1.s2     Document Type: Article

References (98)

1. Koller WC, Montgomery EB. Issues in the early diagnosis of Parkinson's disease. Neurology 1997;49(Suppl 1):S10-S25.
2. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49(Suppl 1):S26-S33.
3. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997;49(Suppl 1):S34-S48.
4. Waters CH. Managing the late complications of Parkinson's disease. Neurology 1997;49(Suppl 1):S49-S57.
5. Aminoff MJ. Treatment of Parkinson's disease. West J Med 1994;161:303-308.
6. Aquilonius SM, Hartvig P. A Swedish county with unexpectedly high utilization of anti-parkinsonian drugs. Acta Neurol Scand 1986;74:379-382.
7. Koller W, Vetere-Overfield B, Gray C, et al. Environmental risk factors in Parkinson's disease. Neurology 1990;40:1218-1221.
8. Rybicki BA, Johnson CC, Uman J, Gorell JM. Parkinson's disease mortality and the Industrial use of heavy metals in Michigan. Mov Disord 1993;8:87-92.
9. Schapira AHV. Advances in the understanding of the cause of Parkinson's disease [editorial]. J Roy Soc Med 1994;87:373-375.
10. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(Suppl 3):S32-S37.
11. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19-108-112.
12. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507.
13. Carvey PM, Ptak LR, Lo ES, et al. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesenphalic tegmentum cultures. Exp Neurol 1991;114:28-34.
14. Mena MA, Pardo B, Caserejos MJ, Fahn S, Garcia de Yebenes JG. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992:7:23-31.
15. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
16. Zigmond MJ, Hastings TG, Abercrombie ED. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Ann NY Acad Sci 1992;648:71-86.
17. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
18. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989;39:1187-1190.
19. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-282.
20. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy in Parkinson's disease. Neurology 1989;39(Suppl 2): S7-S10.
21. Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double-blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 1989;4:303-309.
22. Mouradian MM, Heuser JD, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
23. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987;22:475-479.
24. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24: 366-371.
25. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989;168: 291-298.
26. LeWitt PA. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. Neurology 1992; 42(Suppl 1):S29-S32.
27. Block G, Liss C, Reines S, et al. Comparison of immediate release and controlled release carbidopa/levodopa in PD. Eur Neurol 1997;37:23-27.
28. Cedarbaum JM, Schleifer LS. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: McGraw-Hill, 1993:463-484.
29. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
30. Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
31. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The Scientific Basis for the treatment of Parkinson's Disease. Carnforth: Parthenon Publishing Group, 1992: 89-112.
32. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41: 202-205.
33. Koller WC. Initiating treatment of Parkinson's disease. Neurology 1992;42(Suppl 1):33-38.
34. Stern MB. Parkinson's disease: early diagnosis and management. J Fam Pract 1993;36:439-446.
35. Olanow CW. MAO-B inhibitors in Parkinson's disease. Adv Neurol 1993;60:666-671.
36. Wessel K, Szelenyi I. Selegiline: an overview of its role in the treatment of Parkinson's disease. Clin Investig 1992;70:459-462.
37. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
38. Olanow CW, Calne DC. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1991;42(Suppl 4):S13-S26.
39. Carrillo MC, Kanai S, Nokubo M, Kitani K. L-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991;48:517-521.
40. Clow A, Hussain T, Glover V, Sandier M, Dexter DT, Walker M. L-Deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1991;86:77-80.
41. Tatton WG, Ansari K, Ju W, Salo PT, Yu PH. Selegiline induces "trophic-like" rescue of dying neurons without MAO inhibition. Adv Exp Med Biol 1995;363:15-16.
42. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. L-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
43. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
44. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371.
45. Vingerhoets FJG, Uitti RJ, Calne DB. Deprenyl and the issue of neuroprotection [editorial]. Eur Neurol 1994;34:1-3.
46. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
47. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
48. Lees AJ, on Behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995;311:1602-1607.
49. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40:841-845.
50. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992;13:339-351.
51. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 1994;657:207-213.
52. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(Suppl 3):S6-S12.
53. Carter AJ, Muller RE. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
54. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995; 18:34-42.
55. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.
56. De Keyser J, De Backer JP, Wilczak N, Herroelen L. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1147-1154.
57. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-393.
58. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-387.
59. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A), a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
60. Rinne UK. Treatment of "de novo" parkinsonian patients: the role of Cabergoline. Proceedings of the Fourth International Congress of Movement Disorders, 16-21 June 1996, Vienna, Austria.
61. Ahlskog JE, Muenter MD. Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clin Proc 1988;63: 969-978.
62. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm Suppl 1995;45:231-238.
63. 2 agonist, ropinirole, as adjunct therapy [abstract]. Neurology 1991; 41(Suppl 1):A399.
64. Diamond SG, Markham CH, Treciokas LI. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985;35:291-295.
65. Kreider M, Knox S. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstract]. Neurology 1996;46(Suppl):A475.
66. Lieberman AN, Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol Rev 1985;37:217-227.
67. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
68. Rascol O, Lees AJ, Senard JM, Pirtosek D, Murray G. Ropinirole: a double-blind placebo-controlled study of efficacy and safety as adjunct therapy in Parkinsonian patients with on-off fluctuations. Neurology 1993;43(Suppl 2):A348.
69. Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease: a seven-year follow-up. Acta Neurol Scand 1990;81:383-387.
70. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
71. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
72. The Bromocriptine Multicentre Trial Group. Bromocriptine as initial therapy in elderly parkinsonian patients. Age Ageing 1990;19:62-67.
73. Nakanishi T, Iwata M, Goto I, et al. Nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol 1992;32(Suppl 1): 9-22.
74. Korczyn A. A double-blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease [abstract]. Neurology 1996;46(Suppl):A159.
75. Rascol O. A double blind L-dopa controlled study of ropinirole patients with early Parkinson's disease [abstract]. Neurology 1996;46(Suppl):A139.
76. Wheadon DE, Wilson-Lynch K, Gardiner D, Kreider MS. Ropinirole, a non-ergoline D2 agonist, is effective in early parkinsonian patients not treated with L-dopa [abstract]. Neurology 1996;46(Suppl):A159.
77. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
78. Shannon KM. New alternatives for the management of early Parkinson's disease [abstract]. Mov Disord 1996;11(Suppl 1): 266.
79. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
80. Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206.
81. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198.
82. Lieberman A. Efficacy and safety of pramipexole in advanced Parkinson's disease patients with the "wearing-off" phenomenon [abstract]. Neurology 1996;46(Suppl):A475.
83. Olsson JE, Rascol A, Korten JJ, Dupont E, Gauthier G. Early treatment with a combination of bromocriptine and levodopa compared with levodopa monotherapy in the treatment of Parkinson's disease. Curr Ther Res 1989;46:1002-1014.
84. Stacy M, Brownlee HJ. Treatment options for early Parkinson's disease. Am Fam Physician 1996;53:1281-1287.
85. Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Trans 1995;45(Suppl):213-224.
86. Ahlskog JE. Treatment of Parkinson's disease: from theory to practice. Postgrad Med 1994;95:52-69.
87. Ordenstein L. Sur la paralysie et la sclerose en plague generalise. Paris: Martinet, 1867.
88. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208:1168-1170.
89. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic applications? Clin Neurol Neurosurg 1992;94(Suppl): S4-S6.
90. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994;44:2685-2688.
91. Mannisto PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317-323.
92. Kolchinsky A. One step closer to gene therapy for Parkinson's disease. Surg Neurol 1996;45:211-212.
93. Suhr ST, Gage FH. Gene therapy for neurologic disease. Arch Neurol 1993;50:1252-1268.
94. Widner H. Immature neural tissue grafts in Parkinson's disease. Acta Neurol Scand 1993;146(Suppl):43-45.
95. Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol 1995;37:776-783.
96. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995;346:1383-1387.
97. Caparros-Lefebvre D, Blond S, Vermersch P, Pecheux N, Guieu JD, Petit H. Chronic thalamic stimulation improves tremor and levodopa-induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:268-273.
98. Iacono RP, Lonser RR, Maeda G, et al. Chronic anterior pallidal stimulation for Parkinson's disease. Acta Neurochir 1995; 137:106-112.